A
Anthony D. Ho
Researcher at University Hospital Heidelberg
Publications - 647
Citations - 31389
Anthony D. Ho is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Transplantation & Stem cell. The author has an hindex of 84, co-authored 636 publications receiving 28430 citations. Previous affiliations of Anthony D. Ho include Kyoto University & Huazhong University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.
Wolfgang Wagner,Frederik Wein,Anja Seckinger,Maria Frankhauser,Ute Wirkner,Ulf Krause,Jonathon Blake,Christian Schwager,Volker Eckstein,Wilhelm Ansorge,Anthony D. Ho +10 more
TL;DR: The results have provided a foundation for a more reproducible and reliable quality control using genotypic analysis for defining MSC.
Journal ArticleDOI
Replicative senescence of mesenchymal stem cells: a continuous and organized process.
Wolfgang Wagner,Patrick Horn,Mirco Castoldi,Anke Diehlmann,Simone Bork,Rainer Saffrich,Vladimir Benes,Jonathon Blake,Stefan M. Pfister,Volker Eckstein,Anthony D. Ho +10 more
TL;DR: The studies indicate that replicative senescence of MSC preparations is a continuous process starting from the first passage onwards, which includes far reaching alterations in phenotype, differentiation potential, global gene expression patterns, and miRNA profiles that need to be considered for therapeutic application of M SC preparations.
Journal ArticleDOI
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh,Joerg Schubert,Marita Ziepert,Rudolf Schmits,Martin Mohren,Eva Lengfelder,Marcel Reiser,Christina Nickenig,Michael R. Clemens,Norma Peter,Carsten Bokemeyer,Hartmut Eimermacher,Anthony D. Ho,Martin Hoffmann,Roland Mertelsmann,Lorenz Trümper,Leopold Balleisen,Ruediger Liersch,Bernd Metzner,Frank Hartmann,Bertram Glass,Viola Poeschel,Norbert Schmitz,Christian Ruebe,Alfred C. Feller,Markus Loeffler +25 more
TL;DR: In a multivariate analysis that used six cycles of CHOP-14 without rituximab as the reference, and adjusting for known prognostic factors, all three intensified regimens improved 3-year event- free survival and progression-free survival.
Journal ArticleDOI
Human haematopoietic stem cell lineage commitment is a continuous process
Lars Velten,Simon Haas,Simon Raffel,Simon Raffel,Sandra Blaszkiewicz,Saiful Islam,Bianca P. Hennig,Christoph Hirche,Christoph Lutz,Eike C. Buss,Daniel Nowak,Tobias Boch,Wolf-Karsten Hofmann,Anthony D. Ho,Wolfgang Huber,Andreas Trumpp,Marieke A.G. Essers,Lars M. Steinmetz,Lars M. Steinmetz +18 more
TL;DR: Flow cytometric, transcriptomic and functional data at single-cell resolution are integrated to quantitatively map early differentiation of human HSCs towards lineage commitment and provide a basis for the understanding of haematopoietic malignancies.
Journal ArticleDOI
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Norbert Schmitz,Lorenz Trümper,Marita Ziepert,Maike Nickelsen,Anthony D. Ho,Bernd Metzner,Norma Peter,Markus Loeffler,Andreas Rosenwald,Michael Pfreundschuh +9 more
TL;DR: Patients with ALK-negative ALCL, PTCLU, or AITL presenting with IPI > 1 have a poor prognosis and should be considered candidates for novel treatment strategies.